Alain Matthey

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Sélidji Todagbé Agnandji, Angela Huttner, Madeleine E. Zinser et al. · New England Journal of Medicine · 2015 · 413 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Angela Huttner, Julie-Anne Dayer, Sabine Yerly et al. · The Lancet Infectious Diseases · 2015 · 278 citations

Veterinary Medicine, Immunology, Infectious Diseases +16

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

François Curtin, Claudia Guebelin, Claire Bridel et al. · Multiple Sclerosis Journal · 2014 · 65 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

Impact of <i>CYP2D6</i> Functional Allelic Variations on Phenoconversion and Drug–Drug Interactions

Flavia Storelli, Alain Matthey, Sébastien Lenglet et al. · Clinical Pharmacology & Therapeutics · 2017 · 60 citations

Medicine, Pharmacokinetics, Pharmacology +17

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up

François Curtin, Claudia Guebelin, Claire Bridel et al. · Journal of Neuroimmunology · 2015 · 45 citations

Life Sciences, Neurology, Neuroscience +14